A61K 40/4271
Melanoma antigens
Official title: {Melanoma antigens}
A61K40/4271 (Melanoma antigens) appears on 405 US grants and 822 published applications in this corpus.
Search patents in A61K- Granted patents
- 405
- Published applications
- 822
- Assignees
- 385
- Inventors
- 1,323
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 0 |
| 2002 | 3 | 9 |
| 2003 | 3 | 5 |
| 2004 | 3 | 20 |
| 2005 | 1 | 14 |
| 2006 | 3 | 14 |
| 2007 | 2 | 11 |
| 2008 | 5 | 22 |
| 2009 | 3 | 21 |
| 2010 | 13 | 18 |
| 2011 | 11 | 18 |
| 2012 | 11 | 17 |
| 2013 | 15 | 9 |
| 2014 | 8 | 31 |
| 2015 | 11 | 25 |
| 2016 | 15 | 24 |
| 2017 | 18 | 52 |
| 2018 | 18 | 34 |
| 2019 | 23 | 54 |
| 2020 | 19 | 61 |
| 2021 | 36 | 62 |
| 2022 | 49 | 109 |
| 2023 | 18 | 60 |
| 2024 | 36 | 56 |
| 2025 | 34 | 45 |
| 2026 | 29 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Modulation of expression of genes related to T cell exhaustion29 Sep 2026US 12,747,431 B2The Trustees of the University of Pennsylvania
- Immune cells with enhanced cytotoxicity and methods of use thereof29 Sep 2026US 12,747,443 B2Ludwig Institute for Cancer Research
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Cancer antigens and methods14 Jul 2026US 12,680,105 B2Enara Bio Limited
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Tumor-Specific Neoantigens and Methods of Using the Same24 Sep 2026US 2026/0285928 A1Geneos Therapeutics, Inc.
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Tethered interleukin-15 and interleukin-2117 Sep 2026US 2026/0274917 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275285 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein139US 5,840,839 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1998
- Melanoma antigens and their use in diagnostic and therapeutic methods108US 5,844,075 AThe United States of America as represented by the Department of Health and Human Services · 1998
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy98US 8,287,857 B2The United States of America as represented by the Secretary of the Deparment of Health and Human Services · 2012
- Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma79US 6,500,919 B1Introgene B.V. · 2002